APEX (Adaptive Persister Eradication Matrix)

Overview

**SYSTEM CLASSIFICATION** Targeted Adaptive Persister Eradication Matrix and Stratified Biomarker Platform. **PRIMARY MISSION** To systematically eliminate minimal residual disease (MRD) and prevent polyclonal relapse in targeted cancer therapies by identifying and collapsing the YAP/TEAD transcriptomic survival scaffold in drug-tolerant persister cells. **INDUSTRY CHALLENGE** Standard targeted therapies initially induce significant tumor shrinkage, but fail to achieve cure because a subset of cells enters a non-mutational, drug-tolerant persister state. These persister cells survive initial treatment and eventually seed polyclonal relapse. Unselected combination regimens routinely fail due to cumulative toxicity penalties and an inability to distinguish mere pathway output from true survival dependency. **HIGH-LEVEL SOLUTIONS** • **Clonogenic Dependency Stratification:** Validates persister vulnerability using a localized TEAD target-gene panel directly tied to clonogenic frequency reduction via Extreme Limiting Dilution Analysis (ELDA), ensuring drug administration is gated on functional dependency rather than passive gene expression. • **Stratified Combination Dominance:** Implements a population-stratified mathematical dominance model that restricts combination dosing strictly to the biomarker-positive residual disease stratum, guaranteeing net therapeutic superiority even under real-world toxicity-driven dose reduction penalties. • **Multinomial Polyclonal Seeding Track:** Utilizes a conditional logit seeding model extended for polyclonal dynamics, tracking residual clone reactivation vectors from on-treatment biopsies to achieve high statistical power in small clinical cohorts without requiring massive prospective sample sizes. • **Dual-Node Transcriptomic Disruption:** Combines primary targeted agents with selective TEAD autopalmitoylation inhibitors during the minimal residual disease window, disrupting the YAP/TEAD nuclear interaction to trigger synthetic lethality in persister populations. **TARGET APPLICATIONS** • **EGFR-Mutant NSCLC Minimal Residual Disease:** Eradicating drug-tolerant persister cells following primary targeted treatment to delay or eliminate systemic disease progression. • **Extracranial Polyclonal Relapse Prevention:** Suppressing multi-clonal seeding vectors in advanced solid tumors presenting high residual YAP/TEAD transcriptomic scores. • **Companion Diagnostic Stratification:** Deploying residual tissue RNA/IHC companion panels to select patient populations capable of deriving net benefit from combination TEAD inhibition. **PROJECTED PERFORMANCE OBJECTIVES** • Dependency Verification: Direct correlation established between high residual TEAD transcriptomic scores and clonogenic frequency suppression in persister cell models following drug washout. • Cohort Statistical Efficiency: High statistical power achieved in small clinical trial cohorts by leveraging multinomial polyclonal seeding mechanics from paired on-treatment and relapse biopsies. • Stratified Utility Optimization: Positive net therapeutic benefit secured exclusively within the biomarker-selected cohort under real-world combination dose reductions. • Residual Disease Target Capture: High target-capture probabilities achieved by optimizing selection threshold parameters to raise the dependent cell fraction in the treated population. **PARTNERSHIP & NDA-GATED TECHNICAL BRIEF** • **Development Status:** Master Technical Record, Statistical Audit, and Preclinical Protocol Complete. • **Collaboration Request:** Seeking co-development, licensing, clinical trial biobank access, or strategic investment partnerships. • **Notice:** Detailed multinomial likelihood formulations, specific RNA/IHC scoring algorithms, ELDA protocol parameters, and clinical trial cohort stratification designs are strictly withheld and available only under NDA.

Technical Specifications

• DESIGNATION: TERRANEX APEX
• DEVELOPMENT STATUS: In Development / Master Audit Complete
• INTELLECTUAL PROPERTY: Patent Pending
• TECHNICAL REVIEW: NDA Required
• PRIMARY FUNCTION: YAP/TEAD-Targeted Adaptive Persister Cell Eradication
• SYSTEM ARCHITECTURE: Stratified Dual-Node Combination Matrix (TEAD Inhibitor + Primary Kinase Inhibitor)
• TECHNOLOGY CATEGORY: Bio-Synthetic Architecture & Targeted Oncology Therapeutics
• CORE PLATFORM: Transcriptomic Persister Dependency Node
• INTEGRATION STRATEGY: On-Treatment Residual Biopsy Stratification & Multinomial Clone Seeding Tracking
• MANUFACTURING PATH: Synthetic Small-Molecule Formulation & Standard Companion Diagnostic Panel Integration
• SCALABILITY PROFILE: High-throughput RNA/IHC panel integration with low-dose combination dosing protocols
• TARGET APPLICATIONS: EGFR-Mutant NSCLC Residual Disease, Polyclonal Relapse Suppression, Advanced Solid Tumors
• COMMERCIAL PATHWAY: Licensing / Acquisition / Co-Development
• PARTNERSHIP STATUS: Open
• INVESTMENT STATUS: Seeking Strategic Partners
• TECHNOLOGY READINESS: Preclinical Validation & Statistical Modeling Complete

Related Sector Programs & Research Directory

Explore all programs in BIO-SYNTHETIC ARCHITECTURE

Browse all active programs in the TERRANEX Research Directory →